Phase 3 Cystic Fibrosis trials in Ireland

Showing 1 to 25 of 30. Each trial links to its page on Pharma Observatory.

• A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy NCT05444257·Phase 3·Active, not recruiting·Vertex Pharmaceuticals Incorporated·Started 2022
• A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation NCT05076149·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2021
• A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF) NCT05033080·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2021
• Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older NCT04183790·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2020
• Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy NCT04058366·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2019
• A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes) NCT04058353·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2019
• A Study Evaluating the Long-term Safety of VX-445 Combination Therapy NCT04043806·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2019
• Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age NCT03691779·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2018
• A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy NCT03447262·Phase 3·Terminated·Vertex Pharmaceuticals Incorporated·Started 2018
• A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis NCT03559062·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2018
• A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F) NCT03460990·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2018
• A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation NCT03537651·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2018
• A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) NCT03447249·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2018
• A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation NCT03277196·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2017
• A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation NCT02725567·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2016
• A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation NCT02565914·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2015
• A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor NCT02412111·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2015
• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor NCT02347657·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2015
• A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis NCT01931839·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2013
• A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation NCT01807923·Phase 3·Completed·Vertex Pharmaceuticals Incorporated·Started 2013
• Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection NCT01316276·Phase 3·Completed·Insmed Incorporated·Started 2012
• Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections NCT01315678·Phase 3·Completed·Insmed Incorporated·Started 2012
• Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients NCT01455675·Phase 3·Completed·Mukoviszidose Institut gGmbH·Started 2011
• Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients NCT01270347·Phase 3·Completed·Amgen·Started 2011
• Tiotropium Bromide in Cystic Fibrosis NCT01179347·Phase 3·Completed·Boehringer Ingelheim·Started 2010